This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

14 Mar 2012

Indian Patent Office Grants First Compulsory License to Generic Company

India's Natco Pharma has been granted a compulsory license to sell a generic version of Bayer's patented cancer drug Nexavar.

The Indian Patent Office has issued its first compulsory license to an Indian pharmaceutical company.


Natco Pharma has been granted the license to sell a generic version of Bayer's cancer drug Nexavar, and Natco intends to market its product, to be called Sorefinat, by the end of March 2012.


Natco chief final officer Bhaskar Narayana confirmed the release of the drug, citing a significantly cheaper price in comparison to the cost at which Bayer markets the branded version of the drug. "We will be sell it at Rs8,800 for a bottle of 120 tablets (one month dose), against around Rs28,000 that Bayer charges for Nexavar," said Narayana.


Despite the issue of a c

Related News